Regeneron Pharmaceuticals (REGN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put REGN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 13%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
Regeneron must continue advancing its clinical pipeline to justify its current valuation. Revenue grew 17% year over year, and the latest quarter beat expectations. It trades at 17× P/E versus a peer median of 22×, indicating the price reflects less growth than forecasted. If Regeneron cuts guidance on the next call, that could negatively impact the stock. Peer multiples imply a price about 4% below where it trades. Our read remains intact; the reason to own it still holds.
Trailing returns as of 2026-09-14. REGN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering REGN (as of Sep 2026).
Based on 15 Wall Street analysts offering 12-month price targets for REGN in the last 4 months.
Continue this research
Compare REGN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| REGN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put REGN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Lawsuits could impact pipeline and regulatory approvals.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $793.74
The last 12 months of price, then the range of analyst 12-month targets from today’s $793.74.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Maintain and grow key product sales including Dupixent, EYLEA HD, Libtayo
Highlights growth in key product Dupixent and EYLEA HD.

Advances: Advance clinical pipeline with ~50 candidates and new approvals
EYLEA HD and Dupixent are key growth drivers.

Advances: Advance clinical pipeline with ~50 candidates and new approvals
Conference highlights growth potential in clinical pipeline.

Class action lawsuit may impact investor confidence.
Advances: Advance clinical pipeline with ~50 candidates and new approvals
FDA approval supports clinical pipeline advancement.

FDA approval supports growth in clinical pipeline.

Expanded collaboration enhances product sales potential.
